Lunsekimig clinical trials
Also written SAR443765.
How each study uses lunsekimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lunsekimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test lunsekimig.
- Jun 2027Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaPhase 2 · Sanofi
Studies
Open first, then newest update. How each study uses lunsekimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeRecruitingPhase 3SanofiNCT07190222Written as Lunsekimig
- A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)Enrolling by invitationPhase 3SanofiNCT07793409Written as Lunsekimig
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeRecruitingPhase 3SanofiNCT07190209Written as Lunsekimig
- Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaEnrolling by invitationPhase 2SanofiNCT06609239Written as Lunsekimig
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyActive, not recruitingPhase 2SanofiNCT06914908Written as Lunsekimig
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaActive, not recruitingPhase 2SanofiNCT06676319Written as Lunsekimig
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 2SanofiNCT06454240Written as lunsekimig
- A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisCompletedPhase 2SanofiNCT06790121Written as Lunsekimig
- Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaCompletedPhase 2SanofiNCT06102005Written as Lunsekimig
- First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic ParticipantsCompletedPhase 1SanofiNCT05366764Written as SAR443765
Codes
What other systems call lunsekimig · ClinicalTrials.gg INT018282
- UNII (FDA) VYR5R5XN5ALUNSEKIMIGOne source FDA
- NCI Thesaurus C203158LunsekimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VYR5R5XN5A | LUNSEKIMIG | One source FDA |
| NCI Thesaurus | C203158 | Lunsekimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.